HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christoph Schwering Selected Research

Enzyme Replacement Therapy

1/2024Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.
10/2022Therapeutic Management of COVID-19 in a Pediatric Patient with Neurodegenerative CLN2 Disease and ICV-Enzyme Replacement Therapy: A Case Report.
1/2021Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christoph Schwering Research Topics

Disease

4Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis)
01/2024 - 01/2021
1Disease Progression
11/2022
1COVID-19
10/2022
1Pain (Aches)
12/2021
1Infections
01/2021

Drug/Important Bio-Agent (IBA)

2cerliponase alfaIBA
01/2024 - 12/2021
1Tripeptidyl-Peptidase 1IBA
01/2024
1Retinaldehyde (Retinal)IBA
11/2022
1lipopigmentsIBA
05/2022

Therapy/Procedure

3Enzyme Replacement Therapy
01/2024 - 01/2021
1Critical Care (Surgical Intensive Care)
10/2022
1Therapeutics
10/2022
1Enzyme Therapy
10/2022
1Intraventricular Infusions
01/2021